Subcutaneous Herceptin Meets Goals In Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
New subcutaneous formulation of Roche's breast cancer biologic Herceptin is comparable to intravenous version, prompting the companies to file for approval in Europe in 2012. Yet, U.S. filing could take longer.